Patients with positive fecal screening test, sooner is better for colonoscopy

April 25, 2017

The risk of colorectal cancer increased significantly when colonoscopy was delayed by more than nine months following a positive fecal screening test, according to a large Kaiser Permanente study published today in the Journal of the American Medical Association.

"With this study we have strong evidence that a colonoscopy should be performed within several months of a positive fecal screening test," said lead author Douglas A. Corley, MD, PhD, a Kaiser Permanente gastroenterologist and research scientist in Northern California.

The fecal immunochemical test, known as FIT, screens for colorectal cancer by detecting small amounts of blood in the stool. When blood is detected, gastroenterologists perform a colonoscopy to detect and possibly remove cancerous or pre-cancerous polyps before there are any symptoms.

The JAMA study reviewed time-to-colonoscopy for 70,124 Kaiser Permanente members in California between 50 and 75 years old with an average risk for colorectal cancer, who had positive FIT results from 2010 through 2013. About 40 percent received follow-up colonoscopies within one month, 64 percent within two months and 74 percent within three months.

Compared with colonoscopy follow-up times of eight to 30 days, the study found no significant differences in risk for any colorectal cancer or an advanced cancer with colonoscopy follow-up times of two, three, four, six, seven or nine months. By 10 to 12 months, however, the risk of any colorectal cancer increased by approximately 50 percent and the risk of an advanced cancer almost doubled. Waiting longer than 12 months increased the risks even more, to more than double the risk for any cancer and triple the risk for an advanced cancer.

In the study, 3 percent of the people with positive FIT results were diagnosed with colorectal cancer (2,191 total cases). Less than 1 percent of these (601 cases) were advanced cancers. The study results were adjusted for differences between patients who had earlier versus later exams.

The findings should help to alleviate anxiety for people who have a positive FIT result, said Kaiser Permanente gastroenterologist Theodore R. Levin, MD, the study's senior author and clinical lead for colorectal cancer screening in Kaiser Permanente's Northern California Region.

"It is a lot of effort for patients to arrange a colonoscopy, given the need for time off work and scheduling someone to accompany them home," Dr. Levin said. "Our study shows that you should get your colonoscopy done, and you should do it as soon as is feasible, but any time within a few months -- which is our goal at Kaiser Permanente -- is reasonably safe based on these data."

Colorectal cancer is the second-leading cause of cancer death in the United States, according to the U.S. Centers for Disease Control and Prevention. The U.S. Preventive Services Task Force recommends that people at average risk be screened with a fecal test every year between the ages 50 and 75, a colonoscopy every 10 years, or flexible sigmoidoscopy every five years. FIT does not require any dietary or medication restrictions and can be completed entirely by mail.

With implementation of annual fecal screening in addition to colonoscopy or sigmoidoscopy screening, Kaiser Permanente continues to meet or exceed the American Cancer Society's target screening rate of 80 percent.

"Until this study, very little evidence was available regarding when colorectal cancer begins to progress," said co-author Joanne Schottinger, MD, chair of the Regional Cancer Committee for the Southern California Permanente Medical Group. "Our research confirms that it is very important for patients to have a colonoscopy within a few months of receiving a positive FIT screening."
-end-
In addition to Drs. Corley, Levin and Schottinger, study co-authors were Christopher D. Jensen, PhD, MPH, Jeffrey Lee, MAS, Amy R. Marks, MPH, Wei K. Zhao, MPH, Charles Quesenberry, PhD, and Bruce Fireman, MA, of the Kaiser Permanente Northern California Division of Research; Virginia P. Quinn, PhD, MPH, Nirupa R. Ghai, PhD, and Richard Contreras, MS, of Kaiser Permanente Southern California Department of Research & Evaluation; Alexander T. Lee, MD, of the Kaiser Permanente Woodland Hills Medical Center; Chyke A. Doubeni, MD, MPH, University of Pennsylvania; and Ann G. Zauber, PhD, Memorial Sloan Kettering Cancer Center.

About the Kaiser Permanente Division of Research

The Kaiser Permanente Division of Research conducts, publishes, and disseminates epidemiologic and health services research to improve the health and medical care of Kaiser Permanente members and society at large. It seeks to understand the determinants of illness and well-being, and to improve the quality and cost-effectiveness of health care. Currently, DOR's 500-plus staff is working on more than 400 epidemiological and health services research projects. For more information, visit http://www.dor.kaiser.org or follow us @KPDOR.

About the Kaiser Permanente Southern California Department of Research & Evaluation

The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiologic research, health services research, biostatistics research, and behavioral research as well as clinical trials. Major areas of study include chronic disease, infectious disease, cancer, drug safety and effectiveness, and maternal and child health. Headquartered in Pasadena, California, the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general public. Visit kp.org/research or follow us on Twitter at @KPSCalResearch

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 11.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/share.

Kaiser Permanente

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.